Rongfei Wei

Dr. Rongfei Wei


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Molecular Immunology
Verified
Journal Article
Closed access
JGJing Guo
Jing Guo
XQXiao Qiu
Xiao Qiu
LZLuo Zhang
Luo Zhang
RWRongfei Wei
Rongfei Wei

1 May 2016 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
JSJingyi Shu
Jingyi Shu
CLChao Liu
Chao Liu
RWRongfei Wei
Rongfei Wei
PXPing Xie
Ping Xie
SHShan He
Shan He
LZLingqiang Zhang
Lingqiang Zhang

1 September 2020 in Translational Oncology
Verified
Journal Article
Open access
JGJing Guo
Jing Guo
Guiying XuGuiying Xu
Guiying Xu
Chuanbin MaoChuanbin Mao
Chuanbin Mao
RWRongfei Wei
Rongfei Wei
Despite the side effects, chemotherapy is one of the most common treatments in colorectal cancer (CRC). An open-ended question about CRC chemotherapy, which has been discussed quite often, is with respect to the validation of prognostic or predictive factors. It is believed that personalized chemotherapy can improve the treatment outcome of patients with colorectal tumors. Though, Smurf1 is highly expressed in multiple tumors and plays a critical role in the occurrence and development of multiple cancers, it's role in the susceptibility of CRC response to chemotherapy is still unknown, Therefore, the study aimed to understand the role of Smurf1 in the susceptibility of CRC response to chemotherapy. The study showed that the knockdown of Smurf1 increases gemcitabine and cisplatin-induced HCT116 cells apoptosis in vitro. Furthermore, in vivo experiments showed that tumors that had low Smurf1 expression exhibited enhanced gemcitabine, cisplatin, and gemcitabine plus cisplatin anti-tumor effects in HCT116 cell-derived xenograft (CDX) models and patient-derived xenograft (PDX) models. In conclusion, the results indicated that Smurf1 inhibits the chemosensitivity of CRC to gemcitabine, cisplatin, and gemcitabine plus cisplatin. Therefore, downregulati1ng the Smurf1 expression is a potential strategy to increase the efficacy of gemcitabine and cisplatin in CRC patients.

3 April 2017 in FEBS Letters
Verified
Journal Article
Closed access
PDF file
RWRongfei Wei
Rongfei Wei
JGJing Guo
Jing Guo
MLMengyuan Li
Mengyuan Li
XYXingjiu Yang
Xingjiu Yang
RZRuimin Zhu
Ruimin Zhu
RGRan Gao
Ran Gao

1 April 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
JGJing Guo
Jing Guo
XZXiangwen Zhan
Xiangwen Zhan
Guiying XuGuiying Xu
Guiying Xu
Chuanbin MaoChuanbin Mao
Chuanbin Mao
RWRongfei Wei
Rongfei Wei
IL-1R8, also known as the Single immunoglobin interleukin-1 (IL-1)-related receptor (Sigirr), has been demonstrated as a negative regulator of IL-1R and Toll-like receptor (TLR) downstream signaling pathways and inflammation. However, the role of IL-1R8 in macrophage migration and proliferation remains unknown. Here we investigated transcriptome profiles of WT and Il1r8-deficient splenocytes and found that innate immunity and cell migration related pathways were significantly correlated with IL-1R8 expression. Cell migration-related genes were downregulated in Il1r8-/- splenocytes or IL-1R8-depleted RAW264.7 cells. Further experiments revealed that IL-1R8-depleted RAW264.7 cells or Il1r8-/- BMDMs exhibited impaired cell migration. Moreover, we found that IL-1R8 suppresses macrophage proliferation through p38 MAPK signaling pathway. Therefore, our study suggests that IL-1R8 is a new positive regulator for macrophage migration and suppresses macrophage proliferation.

1 October 2017 in Cellular Signalling
Verified
Journal Article
Closed access
RWRongfei Wei
Rongfei Wei
BLBaoliang Li
Baoliang Li
JGJing Guo
Jing Guo
MLMengyuan Li
Mengyuan Li
RZRuimin Zhu
Ruimin Zhu
RGRan Gao
Ran Gao